Incurable, progressive Merkel cell carcinoma: A single‐institution study of 54 cases

Incurable, progressive Merkel cell carcinoma: A single‐institution study of 54 cases Key PointsThe median overall survival, disease‐free survival and survival from disease progression of patients with progressive disease were 15, 8 months and 5 months, respectively.Twenty‐two (96%) of 23 individuals suffering from disease progression died of the disease. The overall mortality rate was 70%.Patients with progressive MCC spend significantly more tumour‐related days in the hospital compared to patients without a progressive disease.The rate of immunosuppression was significantly higher in the MCC progressive group and those patients received more often radio‐ and/or chemotherapy.Despite an aggressive therapy approach and long hospitalisation, survival among patients suffering from progressive MCC was very poor. Randomised clinical trials are required to assess whether aggressive systemic and local therapy is justified in Merkel cell carcinoma patients with progressive disease.INTRODUCTIONMerkel cell carcinoma is an aggressive and fast‐growing neuroendocrine tumour of the skin. It occurs predominantly on sun‐exposed skin of elderly and/or immunosuppressed people.Approximately 4% of all patients with Merkel cell carcinoma initially present with distant metastases, a stage, where palliative treatment is usually considered. Very limited data are available on palliative treatment in patients suffering from Merkel cell carcinoma. A multimodal radio/chemotherapy concept is advisable for patients suffering from an advanced tumour stage or patients who are not http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Otolaryngology Wiley

Incurable, progressive Merkel cell carcinoma: A single‐institution study of 54 cases

Loading next page...
 
/lp/wiley/incurable-progressive-merkel-cell-carcinoma-a-single-institution-study-6s0YWX0AWl
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 John Wiley & Sons Ltd
ISSN
1749-4478
eISSN
1749-4486
D.O.I.
10.1111/coa.12996
Publisher site
See Article on Publisher Site

Abstract

Key PointsThe median overall survival, disease‐free survival and survival from disease progression of patients with progressive disease were 15, 8 months and 5 months, respectively.Twenty‐two (96%) of 23 individuals suffering from disease progression died of the disease. The overall mortality rate was 70%.Patients with progressive MCC spend significantly more tumour‐related days in the hospital compared to patients without a progressive disease.The rate of immunosuppression was significantly higher in the MCC progressive group and those patients received more often radio‐ and/or chemotherapy.Despite an aggressive therapy approach and long hospitalisation, survival among patients suffering from progressive MCC was very poor. Randomised clinical trials are required to assess whether aggressive systemic and local therapy is justified in Merkel cell carcinoma patients with progressive disease.INTRODUCTIONMerkel cell carcinoma is an aggressive and fast‐growing neuroendocrine tumour of the skin. It occurs predominantly on sun‐exposed skin of elderly and/or immunosuppressed people.Approximately 4% of all patients with Merkel cell carcinoma initially present with distant metastases, a stage, where palliative treatment is usually considered. Very limited data are available on palliative treatment in patients suffering from Merkel cell carcinoma. A multimodal radio/chemotherapy concept is advisable for patients suffering from an advanced tumour stage or patients who are not

Journal

Clinical OtolaryngologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off